No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
Antoinette Hollestelle(Erasmus MC Cancer Institute), Saundra S. Buys(University of Utah), Maria Bisogna(Memorial Sloan Kettering Cancer Center), Katja K.H. Aben(Radboud University Nijmegen), Yukie T. Bean(Oregon Health & Science University), Volker Arndt(German Cancer Research Center), Elisa V. Bandera(Rutgers, The State University of New Jersey), Elisa Alducci(Istituto Oncologico Veneto), Hiltrud Brauch(German Cancer Research Center), Ralf Bützow(Helsinki University Hospital), Natalia Bogdanova(Medizinische Hochschule Hannover), Banu Arun(The University of Texas Health Science Center at Houston), Laura Baglietto, Thomas Brüning(Institute for Prevention and Occupational Medicine), Line Bjørge(Haukeland University Hospital), Anders Bojesen(Vejle Sygehus), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Andrew Berchuck(General Marble (Greece)), Antonis C. Antoniou(Weatherford College), Daniel Barrowdale(University of Cambridge), Matthias W. Beckmann(Universitätsklinikum Erlangen), Agnieszka Budziłowska(The Maria Sklodowska-Curie National Research Institute of Oncology), Irene L. Andrulis(University of Toronto), Javier Benı́tez(Spanish National Cancer Research Centre), Bjarni A. Agnarsson(Reykjavík University), Joan Brunet(Institut Català d'Ornitologia), Norbert Arnold(Christian-Albrechts-Universität zu Kiel), Carl Blomqvist(University of Helsinki), Raanan Berger(Tel Aviv University), Lars Beckmann(German Cancer Research Center), Louise A. Brinton(National Cancer Institute), Stig E. Bojesen(University of Copenhagen), Hermann Brenner(Universidad de Granada), Hoda Anton‐Culver(University of California, Irvine), Bernardo Bonanni(European Institute of Oncology), Frederieke H. van der Baan(Dutch Cancer Society), Rosemary L. Balleine(The University of Sydney), Judith S. Brand(Institute of Cancer Research), Barbara Burwinkel(German Cancer Research Center), Brita Arver(Karolinska University Hospital), Natalia Antonenkova(N.N. Alexandrov National Cancer Centre), Sharon E. Johnatty(University of Southern California), Fiona Bruinsma(The Netherlands Cancer Institute), Alan Ashworth(University of California, San Francisco), Kristiina Aittomäki(University of Helsinki), Andreas Berger(Comprehensive Cancer Center Vienna), Carmel Apicella(The University of Melbourne), Clareann H. Bunker(University College London Hospitals NHS Foundation Trust), Manjeet K. Bolla(University of Cambridge), Angela Brooks‐Wilson(BC Cancer Agency)
Cited by 20
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
|JAMA Oncology|2016|6.3k
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.4k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
|Nature Genetics|2010|3k